NCT00000820View on ClinicalTrials.gov

A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 2002

Conditions
HIV Infections
Interventions
DRUG

Aldesleukin

Trial Locations (10)

10003

Beth Israel Med. Ctr. (Mt. Sinai), New York

10016

NY Univ. HIV/AIDS CRS, New York

10021

Cornell University A2201, New York

14215

SUNY - Buffalo, Erie County Medical Ctr., Buffalo

19104

Hosp. of the Univ. of Pennsylvania CRS, Philadelphia

35294

Alabama Therapeutics CRS, Birmingham

44106

Case CRS, Cleveland

80262

University of Colorado Hospital CRS, Aurora

275997215

Unc Aids Crs, Chapel Hill

462025250

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH